A Study to Optimize Controlled Human Malarial Infection by Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults
Sanaria Inc.'s study aims to optimize controlled human malarial infection (CHMI) using PfSPZ, targeting healthy adults aged 18-45. The successful establishment of a reliable infection model could enhance the development of malaria vaccines and therapeutics, positioning Sanaria favorably in the malaria prevention market. Given the global burden of malaria, particularly in endemic regions, advancements in this area could attract significant interest from public health organizations and potential partnerships with pharmaceutical companies. The study's completion may also provide valuable data for future clinical trials, enhancing Sanaria's competitive edge in the malaria vaccine landscape.
Indication: Malaria
Modality: protein therapy
Target: Plasmodium falciparum sporozoites (PfSPZ)
Sponsor: Sanaria Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Plasmodium falciparum sporozoites (PfSPZ)
View original source fields
Condition raw: Malaria
Condition normalized: Malaria
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Plasmodium falciparum sporozoites (PfSPZ)
Target normalized: Plasmodium falciparum sporozoites (PfSPZ)